This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.
Aged 18-75 years
Histologically or cytologically confirmed non-small cell lung cancer
1-10 metastases on contrast-enhanced MRI
Radiotherapy for extracranial lesions is permitted
Small cell carcinoma of lung
Intracranial metastases needed surgical decompression
Patients with contraindications for MRI
Previous radiotherapy or excision for intracranial metastases
Parallel
MRI-guided adaptive SRT
RadiationMRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.
Conventional SRT
RadiationConventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
Radiation-related brain necrosis incidence rate
"Radiation-related brain necrosis" refers to brain tissue damage that occurs as a result of radiation therapy. It can be detected by brain MRI imaging.
intracranial progression-free survival rate
The percentage of patients who, after one year of treatment, have not experienced any progression of their intracranial disease.
Objective response rate
To evaluate the effectiveness of a treatment for brain tumors based on RECIST 1.1 criteria.
Overall survival
The percentage of patients who are alive after one year of treatment.
Radiation-related Neurotoxicity
"Neurotoxicity" refers to the harmful effects that certain substances or conditions can have on the nervous system, which was examined based on RECIST 1.1 criteria.
Click on the lead sponsor to view all of their trials.
